Brought to you by 
Nycomed gets rights to NPS's Phase III Gattex; rights returned
20 Mar 2013
Executive Summary
NPS Pharmaceuticals licensed Nycomed rights to develop and commercialize its short bowel syndrome (SBS) drug candidate Gattex (teduglutide) worldwide, except in the US, Canada, and Mexico, where NPS retains rights.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nycomed gets rights to NPS's Phase III Gattex; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice